[A19-81] Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2020
Commission awarded on 20.09.2019 by the Federal Joint Committee (G-BA).
Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.